key: cord-0294312-ival5d5c
authors: Hemmi, Takuya; Ainai, Akira; Hashiguchi, Takao; Tobiume, Minoru; Kanno, Takayuki; Iwata-Yoshikawa, Naoko; Iida, Shun; Sato, Yuko; Miyamoto, Sho; Ueno, Akira; Sano, Kaori; Saito, Shinji; Shiwa-Sudo, Nozomi; Nagata, Noriyo; Tamura, Koji; Suzuki, Ryosuke; Hasegawa, Hideki; Suzuki, Tadaki
title: Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
date: 2022-05-25
journal: bioRxiv
DOI: 10.1101/2022.05.24.493348
sha: cbcf5bf13f3babf2512c150623e10a7133486966
doc_id: 294312
cord_uid: ival5d5c

To control the coronavirus disease 2019 (COVID-19) pandemic, there is a need to develop vaccines to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. One candidate is a nasal vaccine capable of inducing secretory IgA antibodies in the mucosa of the upper respiratory tract, the initial site of infection. However, regarding the development of COVID-19 vaccines, there is concern about the potential risk of inducing lung eosinophilic immunopathology as a vaccine-associated enhanced respiratory disease as a result of the T helper 2 (Th2)-dominant adaptive immune response. In this study, we investigated the protective effect against virus infection induced by intranasal vaccination of recombinant trimeric spike protein derived from SARS-CoV-2 adjuvanted with CpG oligonucleotides, ODN2006, in mouse model. The intranasal vaccine combined with ODN2006 successfully induced not only systemic spike-specific IgG antibodies, but also secretory IgA antibodies in the nasal mucosa. Secretory IgA antibodies showed high protective ability against SARS-CoV-2 variants (Alpha, Beta and Gamma variants) compared to IgG antibodies in the serum. The nasal vaccine of this formulation induced a high number of IFN-γ-secreting cells in the draining cervical lymph nodes and a lower spike-specific IgG1/IgG2a ratio compared to that of subcutaneous vaccination with alum as a typical Th2 adjuvant. These features are consistent with the induction of the Th1 adaptive immune response. In addition, mice intranasally vaccinated with ODN2006 showed less lung eosinophilic immunopathology after viral challenge than mice subcutaneously vaccinated with alum adjuvant. Our findings indicate that intranasal vaccine adjuvanted with ODN2006 could be a candidate that can prevent the infection of antigenically different variant viruses, reducing the risk of vaccine-associated enhanced respiratory disease.

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory 55 syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since December 2019 and 56 is presently a major public health concern [1, 2] . Vaccines could be the most promising 57 approach to protect us from the threat of this infectious disease. Burlington, MA). The absorbance at 405 nm was measured using an iMark microplate 179 reader (Bio-Rad, Hercules, CA). All procedures were performed at room temperature. 180

The S-specific IgG antibody titer was defined as the reciprocal of the highest dilution of the test sample, giving a higher absorbance than the cut-off value obtained as 2-fold mean 182 absorbance of serial dilutions of control naive mouse serum set in each plate. 183

Quantification of S-specific IgG1 or IgG2a antibodies in the serum and IgA 184 antibodies in nasal or lung washes was performed as previously described [23] . Chimeric The neutralization assay was performed as previously described [23, 34] . Briefly, 195 50uL of QHmusX (100TCID50) and 50uL of heat-inactivated serum serially diluted by 196 two-fold were mixed and incubated in 96-well microtiter plates for 1h at 37 , followed by the addition of 100 µL of VeroE6-TMPRSS2 cells (JCRB1819, Japanese Collection of 198

Research Bioresources Cell Bank) [35, 36] . After five days of cultivation, samples were 199 examined for viral cytopathic effects (CPEs). Neutralizing antibody titers were 200 determined as the reciprocal of the highest dilution rate at which no CPEs were observed. 201

The neutralization assay was performed in a biosafety level 3 laboratory at the NIID, 202 Japan. 203 204 2.6. Enzyme-linked immunospot assay 205 Cells secreting interferon (IFN)-γ, interleukin (IL)-4, or IL-5 were determined using 206 a mouse enzyme-linked immunospot (ELISpot) assay kit (Mabtech, Cincinnati, OH) 207 according to the manufacturer's instructions. Briefly, in plates pre-coated with 208 anti-mouse IFN-γ, IL-4, or IL-5 antibodies, 3 × 10 5 cells harvested from the spleen or 209 cervical lymph nodes were incubated for 16 h in the presence of a peptide pool derived 210 from the S protein of SARS-CoV-2 (a mixture of PepTivator SARS-CoV-2 Prot_S, S1, 211 and S+; Miltenyi Biotec, Bergisch Gladbach, Germany). After washing the cells with 212 incubated at RT for 2 h, followed by incubation with ALP-conjugated streptavidin at RT 214 for 1 h. The enzymatic reaction was initiated by addition of BCIP/NBT. Each experiment 215 was performed in duplicate. Spots formed by cytokine-secreting cells were counted and 216 analyzed using ELISpot reader S6 Universal with ImmunoSpot 7.0 software (Cellular 217 Technology, Ltd., Shaker Heights, OH). To evaluate the S-specific antibody responses, serum, nasal and lung wash specimens were collected from mice that received three doses of either intranasal or 262 subcutaneous vaccines (Fig. 1A) . Intranasal vaccination was performed with or without 263 ODN2006 as a mucosal adjuvant and subcutaneous vaccination was performed with 264 ODN2006 or alum adjuvant. Naïve mice were used as negative controls. Serum 

To evaluate the protection against viral challenge, intranasal inoculation of the 285 mouse-adapted SARS-CoV-2 strain, QHmusX, was performed on mice vaccinated under 286 the same conditions as described above ( Fig. 2A ). Nasal and lung wash samples were 287 collected at three days post-infection (dpi), and the amount of subgenomic RNA (sgRNA) 288 derived from SARS-CoV-2 in these samples was evaluated by real-time RT-PCR to 289 assess the protection of mice against infection. The number of sgRNA copies in the nasal 290 wash was significantly reduced in mice with S-specific IgA in the nasal mucosa induced 291 by intranasal vaccination adjuvanted with ODN2006 ( Fig. 1D and 2B ). No significant 292 decrease in sgRNA in the nasal mucosa was observed in mice that received subcutaneous 293 vaccine or mice intranasally vaccinated with antigen only. A significant decrease in 294 sgRNA copies in the lung wash was observed in mice vaccinated intranasally or 295 subcutaneously in the presence of ODN2006 or alum, respectively, which showed high 296 neutralizing antibody titers in serum ( Fig. 1C and 2C) . Simultaneously, the mice were 297 monitored for body weight and survival for 10 days after the challenge ( Fig. 2D and 2E) . 298

Naïve mice and those intranasally vaccinated with antigen only died by 6 dpi. Among 299 mice that received subcutaneous vaccine with ODN2006 or alum, although few mice died, 300 others recovered from the apparent decrease in body weight post challenge and survived 301 until 10 dpi; in contrast, all mice intranasally vaccinated with ODN2006 survived without 302 remarkable body weight change during the observation period. 303

In addition, protection against viral challenge with SARS-CoV-2 variants (Alpha, 304

Beta and Gamma variants) was assessed (Fig. 3A ). Significant reductions in nasal sgRNA 305 derived from each variant virus were achieved in mice intranasally vaccinated in the 306 presence of ODN2006 when compared to naïve mice ( Fig. 3B-3D ). In the lungs, sgRNA 307 of Alpha and Gamma variants significantly decreased by both intranasal and 308 subcutaneous vaccination with antigen together with ODN2006, while that of Beta variant presented a significant decrease only by intranasal but not subcutaneous 310 vaccination (Fig. 3E-3G) . 311

These findings indicate that IgA antibodies in the nasal mucosa and lung induced by 312

intranasal, but not subcutaneous, vaccination combined with ODN2006 were 313 cross-protective against SARS-CoV-2 variants. 314 for 20 weeks at 2-week intervals after the initial vaccination (Fig. 4C) . The highest 327 responses were achieved two weeks after the final vaccination, and mice that received 328 subcutaneous vaccine adjuvanted with alum or ODN2006 showed the highest S-specific 329 IgG antibodies, followed by mice intranasally vaccinated in the presence of ODN2006. 330

Although systemic S-specific IgG antibodies slightly declined over time during the 331 observation period, IgG antibodies were well held in mice subcutaneously vaccinated 332

with alum compared to mice that received intranasal or subcutaneous vaccination with 333 ODN2006 (Fig. 4D) . At 20 weeks after the initial vaccination, S-specific nasal IgA 334 antibodies were detected in five out of six mice with intranasal vaccination combined 335 with ODN2006 but not in mice with other vaccinations (Fig. 4E) . Cells isolated from the spleen and cervical lymph nodes one week after the final 351 immunization were evaluated for cytokine production under stimulation of the peptide 352 pool of S protein by ELISpot assay (Fig. 5A ). Significant induction of IFN-γ-secreting 353 cells was observed in the splenocytes of mice subcutaneously vaccinated with ODN2006 354 (Fig. 5B) . In contrast, a significant induction of IL-4-secreting cells was observed in 355 splenocytes obtained from mice subcutaneously vaccinated with alum adjuvant, and a 356 similar tendency was observed in IL-5-secreting cells (Fig. 5C and 5D ). In the case of 357 splenocytes, each cytokine-secreting cell significantly increased in mice that received 358 subcutaneous vaccination with ODN2006 or alum but not in those intranasally vaccinated. 359 Therefore, cytokine-secreting cells were evaluated using cells isolated from the draining 360 cervical lymph nodes of intranasally vaccinated or naive mice. Intranasal vaccination in 361 the presence of ODN2006 significantly increased the number of IFN-γ-secreting cells, 362 while IL-4 and IL-5 secreting cells decreased compared to intranasal vaccines with only 363 antigen (Fig. 5E ). In contrast, intranasal vaccination with antigen in the absence of 364 mucosal adjuvant significantly induced IL-4 and IL-5 secreting cells, but not 365 IFN-γ-secreting cells, in draining lymph nodes (Fig 5F and 5G) . 366

The dominant T cell response was estimated using an S-specific IgG antibody 367 subclass ( Fig. 5H and 5I ). Large amounts of S-specific IgG1 antibodies were obtained in 368 mice subcutaneously vaccinated with alum adjuvant compared to mice immunized in the 369 presence of ODN2006; however, S-specific IgG2a antibodies in mice intranasally or 370 subcutaneously vaccinated in the presence of ODN2006 were higher than those obtained 371 in mice vaccinated with alum. When the S-specific IgG1/IgG2a ratio was calculated, the 372 IgG1/IgG2a ratio after vaccination with ODN2006 was significantly lower than that after vaccination with alum (Fig. 5J) . S-specific IgG1/IgG2a ratios (r = 0.779, p = 0.0015) (Fig. 6C and 6D) . with an adjuvant inducing a Th1-shifted response would be a safe and effective vaccine 476 not only for preparing cross-protective secretory IgA antibodies, but also to reduce the 477 potential risk of VAERD, that is, lung eosinophilic immunopathology. 478 shown as the means ± SD. Each dotted line indicates the detection limit of measurement. 708

The p-values were calculated by Kruskal-Wallis test followed by Dunn's multiple 709 comparison test (*P < 0.05, **P < 0.01). in: intranasally, sc: subcutaneously. 

Epidemiological and clinical 513 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 514 descriptive study

A Novel Coronavirus from 517 Patients with Pneumonia in China

Safety 520 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and 523 Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Oxford-AstraZeneca COVID-19 vaccine efficacy

Respiratory syncytial virus disease in infants despite prior administration of antigenic 604 inactivated vaccine

Single-dose intranasal vaccination elicits systemic and mucosal immunity against

Intranasal administration of a 610 recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse

Food and Drug Administration. Development and licensure of vaccines to 613 prevent COVID-19

Acts as a Potent Cancer Vaccine Adjuvant by Targeting 619 Draining Lymph Nodes

A serological assay to detect SARS-CoV-2 seroconversion in humans

A 625 SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by 626 coordinated recognition of a virus-vulnerable site

Structures of the prefusion form of measles virus fusion protein in complex with 630 inhibitors

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Temporal 639 maturation of neutralizing antibodies in COVID-19 convalescent individuals improves 640 potency and breadth to circulating SARS-CoV-2 variants

Consensus and 643 variations in cell line specificity among human metapneumovirus strains

Enhanced 646 isolation of SARS-CoV-2 by TMPRSS2-expressing cells

spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and 650 protection in mice

Flow 653 cytometric analysis of macrophages and dendritic cell subsets in the mouse lung

Neutralizing-antibody-independent SARS-CoV-2 control correlated with 657 intranasal-vaccine-induced CD8(+) T cell responses

An intranasal 660 vaccine durably protects against SARS-CoV-2 variants in mice

(Th1) and Th2 characteristics start to develop during T cell priming and are 664 associated with an immediate ability to induce immunoglobulin class switching

Omicron-neutralizing memory B cells are elicited by two doses of 668 BNT162b2 mRNA vaccine

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the 672 humoral response to SARS-CoV-2 vaccination

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2

Omicron after breakthrough infection by other variants

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Omicron variant replication in human bronchus and lung ex vivo

Mitigating Covid-19 in the face of emerging virus variants, 685 breakthrough infections and vaccine hesitancy

Characterization 688 and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature

T follicular helper cell differentiation, function, and roles in disease

B cell memory: understanding COVID-19

Each of 12 mice were vaccinated three times at 2-week intervals. Two weeks after the 714 final vaccination, mice were intranasally challenged with mouse adopted SARS

QHmusX, into both lungs and nasal cavity (40 and 6 LD 50 per mouse, respectively)

NW and LW were collected from each of six mice for the evaluation of antibody 717 responses at 3 dpi. Body weight and survival of six mice were monitored 10 days after 718 viral challenge. (B, C) Copy numbers of SARS-CoV-2 subgenomic RNA (sgRNA

NW and LW were evaluated by real-time RT-PCR. Data shown as the geometric mean ± 720 the geometric SD. The p-values were calculated by Kruskal-Wallis test followed by

Dunn's multiple comparison test (*P < 0.05, *** P < 0.001). (D, E) Body weight changes 722 and survival rates during 10 days of observation after challenge with QHmusX. Data 723 shown as the means ± SD. The p-values of body weight and survival were compared with 724 mice intranasally vaccinated with ODN2006 by mixed-model analysis followed by

Dunnett's multiple comparisons test and log-rank (Mantel-Cox) test (**P < 0.01)

Mice were vaccinated three times at 2-week intervals. Two weeks after the final 729 vaccination, each of six mice were intranasally challenged with 3

The p-values were calculated by Kruskal-Wallis test followed by Dunn's multiple 734 comparison test

Germinal center formation and long-lasting antibody responses

GL7 + CD95 + ) among CD19 + B cells was evaluated by flow cytometry in cervical lymph 739 nodes collected from mice one week after third vaccination. Results were shown as the 740 mean ± SD. (C) To evaluate time-course of antibody responses induced by three doses of 741 vaccination, serum samples were collected every two weeks. After 20 weeks from the 742 initial vaccination, serum and NW samples were collected (six mice per group). (D) The 743 changes of optical density

E) S-specific IgA concentration in NW collected at 20 weeks after the initial 745 vaccination was evaluated by ELISA. Results were shown as the mean ± SD. Each dotted 746 line indicates the detection limit of measurement

Kruskal-Wallis test followed by Dunn's multiple comparison test (*P < 0.05, **P < 0

Induction of significant Th1 response by using ODN2006 as an adjuvant

A) Spleen and cervical lymph nodes were collected from individuals shown in

Single cell suspensions obtained from each tissue was cultured under the 753 stimulation of peptide pool of SARS-CoV-2 S protein. Spleen (B-D) or cervical lymph 754 node cells (E-G) were counted on the production of IFN-r (B, E)

ELISpot assay. Data shown as the means ± SD. (H, I) SARS-CoV-2 S-specific

IgG1 and IgG2a antibodies were quantified by ELISA, and (J) IgG1/IgG2a ratio was 757 calculated. Data shown as the geometric means ± geometric SD. The p-values were 758 calculated by Kruskal-Wallis test followed by Dunn's multiple comparison test (*P < 0

We thank A. Kojima The authors declare that they have no known competing financial interests or personal 509 relationships that could have influenced the work reported in this study. 510